Highlights first quarter 2025:

o Q1 revenue reached USD 50.8 million, a 5% increase year-over-year, with
adjusted EBITDA of USD 9.0 million, up 59% from the prior year.
o Human Health Ingredients delivered USD 26.0 million in revenue, up 16% YoY,
driven by good volume growth in multiple markets. Adjusted EBITDA grew 36% to
USD 11.3 million.
o Consumer Health Products generated USD 27.1 million in revenue, an increase of
4% YoY.
o Emerging Business reported USD 2.1 million in revenue, stable compared to
previous quarters
o Human clinical trial on Lysoveta initiated, ambition to build first brain
related claims

"We're off to a good start in 2025, with growth in both revenue and earnings.
Adjusted EBITDA rose 59% year-over-year, reflecting the operational improvements
we've made across the business. Our Human Health Ingredients segment continues
to be the key growth engine, experiencing demand growth across multiple
regions.", said Matts Johansen, CEO of Aker BioMarine.  

Human Health Ingredients delivered a strong quarter, with revenues up 16%
year-over-year, driven by good demand growth in China, Europe, and South
America. Adjusted EBITDA increased 36% year-over-year to USD 11.3 million,
supported by higher volume, improved pricing and lower unit costs. The segment
has now achieved nine consecutive quarters of revenue growth, reflecting the
consistency built through recent operational improvements.

Consumer Health Products returned to year-over-year growth, with revenues up 4%
compared to Q1 last year, although lower sequentially due to normal seasonal
trends. Adjusted EBITDA remained positive, despite slightly lower gross margins
compared to last year, reflecting ongoing cost discipline. The broader market
for FMCG supplements also grew moderately in Q1 at around 3%.

Outlook
The Human Health Ingredients segment sees continued growth, supported by good
underlying demand in multiple markets. In Consumer Health Products, the business
has returned to modest growth, with revenues following market growth. The
Emerging Business segment remains on track toward cash break-even, with active
engagement in potential transactions. At the corporate level, the company has
established a new, leaner cost base and is executing on initiatives to further
improve financial and operational efficiency. 

AKBM is adapting to market trends through productivity and cost measures while
actively assessing the potential impact of increased macroeconomic uncertainty
and new tariffs.

Attached is the quarterly presentation for Q1. Group reported financial figures
can be downloaded in an excel from the company's investor page: Investor -
Analyst information

At 09:00 CET today, the management hosts a webcast. The webcasted presentation
will be in English. To join, please use the link that is available at
www.akerbiomarine.com/investor. 

A replay of the presentation will be made available soon after the presentation
at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP Strategic Finance & IR 
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and
PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.